Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|The Lancet|2019Cited by 581
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed GlioblastomaRoger Stupp, Michael Weller, Monika E. Hegi et al.|Journal of Clinical Oncology|2010Cited by 445
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Martin Glas, Niklas Schäfer et al.|Journal of Clinical Oncology|2016Cited by 197
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastomaDavid A. Reardon, Zariana Nikolova, G. Dresemann et al.|British Journal of Cancer|2009Cited by 130
Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer societyChristoph Kowalski, Simone Wesselmann, Ullrich Graeven et al.|BMC Cancer|2017Cited by 110